Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2019-01-07 Share Issue/Capital Cha…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions" (Monthly information relating to the total number of voting rights and shares) and explicitly references Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and total voting rights as of a specific date (31/12/2018). This structure is characteristic of mandatory periodic disclosures regarding share capital and voting rights, which falls under the category of general regulatory filings or specific capital/share information. Since there is no specific code for 'Monthly Voting Rights Disclosure' and it is a mandatory regulatory disclosure, it fits best under 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). However, given the focus is purely on the count of shares and voting rights, and it's a recurring regulatory report, RNS is the most appropriate general regulatory fallback, although it is a very specific type of filing. Given the options, RNS is the best fit for a mandatory, recurring regulatory disclosure that isn't a full financial report or a specific transaction notice like POS or SHA.
2019-01-07 French
Communicated under the obligation to provide permanent information / Other communications
Transaction in Own Shares Classification · 99% confidence The document explicitly states it is 'Regulated Information – disclosure of trading in own shares' pursuant to the MAR regulation, detailing purchases of its own shares by bioMérieux between December 10 and December 14, 2018. This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance).
2018-12-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Transaction in Own Shares Classification · 100% confidence The document explicitly states it is an 'Information Réglementée – déclaration de transactions sur actions propres' (Regulated Information – declaration of transactions on own shares) and references European Regulation No 596/2014 (MAR) concerning transactions in own shares for the period of December 10 to 14, 2018. This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares. Therefore, the correct classification is 'Transaction in Own Shares' (POS).
2018-12-18 French
Communicated under the obligation to provide permanent information / Other communications
Transaction in Own Shares Classification · 98% confidence The document explicitly states it is a 'Regulated Information – disclosure of trading in own shares' pursuant to the MAR regulation, detailing purchases of its own shares by bioMérieux between December 3 and December 7, 2018. This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category (POS). It is not a general director's dealing (DIRS), which typically refers to insider trades by directors, but rather a corporate transaction involving the company's own stock.
2018-12-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Transaction in Own Shares Classification · 99% confidence The document is titled "Information Réglementée – déclaration de transactions sur actions propres" (Regulated Information – declaration of transactions on own shares) and explicitly states it is made "En application du règlement européen n°596/2014 du 16 avril 2014 sur les abus de marché (« Règlement MAR »)". It details transactions (purchases/acquisitions) of the company's own shares over a specific period (December 3 to 7, 2018). This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS).
2018-12-10 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions" (Monthly information relating to the total number of voting rights and shares) and explicitly references French regulatory articles (Article L. 233-8 II du code de commerce and Article 223-16 du règlement général de l'Autorité des marchés financiers - AMF). It provides a table detailing the number of shares and total voting rights as of a specific date (30/11/2018). This structure is characteristic of mandatory periodic disclosures regarding share capital and voting rights, which often fall under general regulatory announcements or specific capital change notifications. Since it is a monthly update on voting rights and share count, it is most closely related to capital structure changes or general regulatory reporting. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in the number of shares, and 'Regulatory Filings' (RNS) is a general catch-all. However, the specific content—a formal monthly disclosure of total voting rights and shares—is a distinct regulatory requirement. In many contexts, this type of filing is categorized separately, but among the provided codes, it relates most closely to capital structure reporting. Since it is a formal, periodic disclosure mandated by the AMF, and not a specific event like a dividend or a major share transaction, it fits best under the general 'Regulatory Filings' (RNS) as a miscellaneous mandatory disclosure, or potentially 'SHA' if the focus is strictly on the share count change. Given the explicit reference to the AMF regulation for voting rights disclosure, RNS is the safest general regulatory classification if a more specific code like 'SHA' (which usually implies an issuance/buyback event) is not a perfect fit for a simple monthly count update. However, looking closely at the definitions, none perfectly match 'Monthly Voting Rights Disclosure'. Since it is a formal regulatory filing providing key share structure data, RNS is appropriate as a fallback for specific regulatory reports not covered elsewhere. I will classify it as RNS as it is a mandatory regulatory update that doesn't fit the other specific categories like DIV, SHA, or DIRS.
2018-12-04 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.